Motavizumab, RSV, and subsequent wheezing – Authors' reply

Katherine L. O'Brien; Amanda Driscoll; Mathuram Santosham; Laura L. Hammitt; Ruth A. Karron

doi:10.1016/S1473-3099(16)30454-6

Motavizumab, RSV, and subsequent wheezing – Authors' reply

Katherine L. O'Brien, Amanda Driscoll, Mathuram Santosham, Laura L. Hammitt, Ruth A. Karron

Bloomberg School of Public Health

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	1329-1330
Number of pages	2
Journal	The Lancet Infectious Diseases
Volume	16
Issue number	12
DOIs	https://doi.org/10.1016/S1473-3099(16)30454-6
State	Published - Dec 1 2016

ASJC Scopus subject areas

Infectious Diseases

Access to Document

10.1016/S1473-3099(16)30454-6

Cite this

@article{07276b9a790d4c2abd85ad547073d80b,

title = "Motavizumab, RSV, and subsequent wheezing – Authors' reply",

author = "O'Brien, {Katherine L.} and Amanda Driscoll and Mathuram Santosham and Hammitt, {Laura L.} and Karron, {Ruth A.}",

note = "Funding Information: KLO'B, MS, and RAK received grant funding from MedImmune for the trial. LLH reports grants from GlaskoSmithKline and Pfizer, outside the submitted work. AJD declares no competing interests. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2016",

month = dec,

day = "1",

doi = "10.1016/S1473-3099(16)30454-6",

language = "English (US)",

volume = "16",

pages = "1329--1330",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Lancet Publishing Group",

number = "12",

}

TY - JOUR

T1 - Motavizumab, RSV, and subsequent wheezing – Authors' reply

AU - O'Brien, Katherine L.

AU - Driscoll, Amanda

AU - Santosham, Mathuram

AU - Hammitt, Laura L.

AU - Karron, Ruth A.

N1 - Funding Information: KLO'B, MS, and RAK received grant funding from MedImmune for the trial. LLH reports grants from GlaskoSmithKline and Pfizer, outside the submitted work. AJD declares no competing interests. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2016/12/1

Y1 - 2016/12/1

UR - http://www.scopus.com/inward/record.url?scp=85004028274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004028274&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(16)30454-6

DO - 10.1016/S1473-3099(16)30454-6

M3 - Letter

C2 - 27998592

AN - SCOPUS:85004028274

SN - 1473-3099

VL - 16

SP - 1329

EP - 1330

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 12

ER -

Motavizumab, RSV, and subsequent wheezing – Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this